In the latest close session, Pfizer (PFE) was down 1.09% at $24.50. This move lagged the S&P 500's daily gain of 0.23%. Meanwhile, the Dow experienced a rise of 0.34%, and the technology-dominated Nasdaq saw an increase of 0.8%.
Coming into today, shares of the drugmaker had gained 3.86% in the past month. In that same time, the Medical sector gained 5.57%, while the S&P 500 gained 3.57%.
Analysts and investors alike will be keeping a close eye on the performance of Pfizer in its upcoming earnings disclosure. The company's earnings report is set to go public on November 4, 2025. It is anticipated that the company will report an EPS of $0.68, marking a 35.85% fall compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $16.81 billion, down 5.06% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $3.07 per share and a revenue of $63.4 billion, demonstrating changes of -1.29% and -0.36%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for Pfizer. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 2.09% lower. At present, Pfizer boasts a Zacks Rank of #4 (Sell).
Investors should also note Pfizer's current valuation metrics, including its Forward P/E ratio of 8.08. This valuation marks a discount compared to its industry average Forward P/E of 14.44.
Meanwhile, PFE's PEG ratio is currently 0.82. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.61.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 168, placing it within the bottom 32% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
